The GLP‐1 receptor agonist and SGLT‐2 inhibitor categories both demonstrated evidence of statistically significant, increasing usage over time in incident patients with type 2 diabetes. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.